- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04719585
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: RCT
Comparison of Opioid and Duloxetine for Postoperative Pain Control After Total Knee Arthroplasty: Randomized Controlled Trial
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
For patients undergoing TKA for osteoarthritis of the knee joint, pain control will be performed using the same pain control technique (pain control using NSAID) until discharge (1 week after surgery) after surgery. By evaluating the Visual Analogue Scale (VAS), which is known as the patient's pain criterion, the study will be conducted only on patients whose score is more severe than 4 points. Among these subjects, only patients who agreed to the study will be assigned to the group taking duloxetine and the group taking opioids with the same probability according to the randomization table for one week after surgery, that is, upon discharge. In our hospital, almost all patients with total knee arthroplasty are discharged one week after surgery, except for special cases such as morbidity of systemic diseases such as cardiopulmonary dysfunction or acute infection after surgery.
Among the co-researchers, one researcher who is in charge of only patient assignment is selected, and the person in charge creates a randomization table through computer generated randomization. During the assignment process, the assignee will not know in advance the next assignment group, and the randomization table is kept in secret. The assignee does not intervene in any other process of this study, and participates only in the task of selecting the assigned group using random checks. The evaluation is evaluated by an evaluator who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study. Such a study plan will be fully explained to the patient in the process of seeking consent for the study before discharge, as it is recorded in detail in the subject description, and only patients who have obtained this consent will be the subject of the study.
This criterion is established because both duloxetine and opioid are not used for all patients after surgery, but for additional pain control after surgery. Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively. In general, if duloxetine is not taken for more than 10 weeks, the frequency of discontinuation syndrome that can occur after discontinuation is remarkably low, so the administration period of 6 weeks was set as the administration period. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
Before surgery, 1 week after surgery, 2 weeks, 6 weeks, 3 months, 6 months, 1 year The degree of pain will be measured using the VAS pain scale, WOMAC pain scale, Brief pain inventory (BPI), Intermittent and Constant Osteoarthritis The pain (ICOAP) score is used to measure additional pain scales in various ways. In addition, SF-36 will be measured before surgery, at 6 weeks, 3 months, 6 months, and 1 year after surgery.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults over age 19
- Patients undergoing total knee arthroplasty for osteoarthritis of the knee joint
- Patients with a pain VAS scale of 4 or more out of 10 after TKA with a pain in the knee joint during daily activities on flat ground
- Patients who are willing or able to follow doctor's instructions, including joint exercises
- Patients not participating in other clinical trials
- Patients who have received sufficient explanation for this clinical trial and agreed to participate
Exclusion Criteria:
- Patients with secondary knee osteoarthritis
- Patients with hypersensitivity reactions and serious side effects to duloxetine or opioid
- Patients with inflammatory arthritis or crystalline arthritis
- Local infection to the lower extremities of the pain area, sepsis, or previous neurological abnormalities.
- Patients who underwent meniscus surgery on the knee joint in the painful area
- If there is construction or deformation of the knee joint in the pain area
- Patients with serious heart-related diseases such as cardiac arrest, a history of cerebral infarction, or ischemic heart disease
- Patients with high blood pressure with poor blood pressure control (Systolic Blood Pressure of> 150 mmHg or Diastolic Blood Pressure> 95 mmHg)
- Patients with abnormal liver function (ALT)> 2.0 times the upper limit of normal (ULN) or blood urea nitrogen (BUN) or serum creatinine> 2.0 times ULN)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Experimental: Duloxetine group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine or opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Comparador activo: Active comparator: Opioid group
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
Prior to discharge, the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group and the opioid-administering group, respectively.
The administration period of duloxetine or opioid is 6 weeks.
The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3 months, 6 months, and 1 year after the TKA surgery.
During the follow-up period, NSAIDs will be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g per day.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Pain Visual Analogue Scale
Periodo de tiempo: changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
score ranges 0 to 10, higher score means more painful
|
changes of the VAS score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
Brief pain inventory (BPI)
Periodo de tiempo: changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
includes 7 categories.
each category score ranges 0 to 10, higher score means more painful
|
changes of the BPI score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24th weeks and 1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
WOMAC(Western Ontario and McMaster University Arthritis Index ) pain scale
Periodo de tiempo: changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).
higher score means more painful.
|
changes of the WOMAC score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
Intermittent and Constant Osteoarthritis pain (ICOAP) score
Periodo de tiempo: changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
11-item tool that assess pain at knee joint.
The 11 items are scored froma 0 to 4 with 0 being no pain and 4 being extreme pain
|
changes of the ICOAP score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
SF-36(Short Form Health Survey - 36) score
Periodo de tiempo: changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
a 36-item, patient-reported survey of patient health.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The lower the score the more disability.
The higher the score the less disability
|
changes of the SF-36 score from the day before TKA operation and at postoperative 1, 2, 6, 12, 24tn weeks and 1 year
|
Range of Motion
Periodo de tiempo: The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
|
The day before TKA operation, postoperative 1, 2, 6, 12, 24 weeks and 1 year
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Complicaciones Postoperatorias
- Dolor
- Manifestaciones neurológicas
- Enfermedades Articulares
- Enfermedades musculoesqueléticas
- Enfermedades reumáticas
- Artritis
- Osteoartritis
- Dolor Postoperatorio
- Artrosis, Rodilla
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes del sistema nervioso periférico
- Analgésicos
- Agentes del sistema sensorial
- Drogas psicotropicas
- Inhibidores de la captación de neurotransmisores
- Moduladores de transporte de membrana
- Agentes antidepresivos
- Agentes de dopamina
- Inhibidores de la recaptación de serotonina y noradrenalina
- Clorhidrato de duloxetina
Otros números de identificación del estudio
- KC20MISI0531
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Duloxetine vs. Opioid
-
Verastem, Inc.TerminadoCáncer de pulmón de células no pequeñas | Mutación Activadora de KRASEstados Unidos, España, Francia, Alemania, Italia
-
Northwestern UniversityNational Institute on Aging (NIA)Activo, no reclutandoDeterioro Cognitivo | Enfermedad de AlzheimerEstados Unidos
-
Verastem, Inc.GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)Activo, no reclutandoCáncer de ovarios | Adenocarcinoma seroso de ovario de bajo gradoEspaña, Estados Unidos, Bélgica, Reino Unido, Francia, Canadá, Italia
-
Gruppo Italiano Studio LinfomiTerminadoEnfermedad de Hodgkin avanzadaItalia
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)ReclutamientoConsolidación de memoriaEstados Unidos
-
University of HelsinkiFinnish Cultural Foundation; University of Oulu; Finnish Work Environment Fund; Juho... y otros colaboradoresDesconocidoLumbalgia | Lumbalgia, RecurrenteFinlandia
-
Hospital Universitari de BellvitgeTerminadoObesidad mórbida | Cirugía bariátricaEspaña
-
Aarhus University Hospital SkejbyDesconocidoSíndrome del seno enfermo | Bloqueo AVDinamarca
-
Menoufia UniversityTerminadoCPRE, canulación difícil del CBDEgipto
-
Centre Hospitalier Régional Metz-ThionvilleTerminado